Assembly Biosciences (ASMB) Competitors

Assembly Biosciences logo
$21.29 +0.17 (+0.80%)
Closing price 04:00 PM Eastern
Extended Trading
$21.29 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ASMB vs. ANIP, PCRX, PAHC, OCUL, and INVA

Should you buy Assembly Biosciences stock or one of its competitors? Assembly Biosciences's main competitors and comparable companies include ANI Pharmaceuticals (ANIP), Pacira BioSciences (PCRX), Phibro Animal Health (PAHC), Ocular Therapeutix (OCUL), and Innoviva (INVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Assembly Biosciences compare to ANI Pharmaceuticals?

Assembly Biosciences (NASDAQ:ASMB) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

In the previous week, ANI Pharmaceuticals had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 8 mentions for ANI Pharmaceuticals and 7 mentions for Assembly Biosciences. ANI Pharmaceuticals' average media sentiment score of 0.40 beat Assembly Biosciences' score of -0.68 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Assembly Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Negative
ANI Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Assembly Biosciences has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 3.5% of Assembly Biosciences shares are owned by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ANI Pharmaceuticals has a net margin of 11.22% compared to Assembly Biosciences' net margin of -16.57%. ANI Pharmaceuticals' return on equity of 28.34% beat Assembly Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Assembly Biosciences-16.57% -4.40% -3.86%
ANI Pharmaceuticals 11.22%28.34%11.18%

ANI Pharmaceuticals has higher revenue and earnings than Assembly Biosciences. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Assembly Biosciences$72.30M5.95-$6.12M$1.0220.71
ANI Pharmaceuticals$883.37M1.84$78.34M$5.0214.23

Assembly Biosciences currently has a consensus target price of $46.50, suggesting a potential upside of 120.17%. ANI Pharmaceuticals has a consensus target price of $100.00, suggesting a potential upside of 39.98%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Assembly Biosciences is more favorable than ANI Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Assembly Biosciences
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
ANI Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.43

Summary

ANI Pharmaceuticals beats Assembly Biosciences on 10 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Pacira BioSciences?

Pacira BioSciences (NASDAQ:PCRX) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Pacira BioSciences presently has a consensus price target of $33.33, suggesting a potential downside of 8.58%. Assembly Biosciences has a consensus price target of $46.50, suggesting a potential upside of 120.17%. Given Assembly Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Assembly Biosciences is more favorable than Pacira BioSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacira BioSciences
0 Sell rating(s)
10 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.09
Assembly Biosciences
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 3.5% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Assembly Biosciences had 6 more articles in the media than Pacira BioSciences. MarketBeat recorded 7 mentions for Assembly Biosciences and 1 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.82 beat Assembly Biosciences' score of -0.68 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company Overall Sentiment
Pacira BioSciences Very Positive
Assembly Biosciences Negative

Pacira BioSciences has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacira BioSciences$726.41M2.01$7.03M$0.35104.17
Assembly Biosciences$72.30M5.95-$6.12M$1.0220.71

Pacira BioSciences has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Pacira BioSciences has a net margin of 5.08% compared to Assembly Biosciences' net margin of -16.57%. Pacira BioSciences' return on equity of 10.82% beat Assembly Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Pacira BioSciences5.08% 10.82% 6.01%
Assembly Biosciences -16.57%-4.40%-3.86%

Summary

Pacira BioSciences beats Assembly Biosciences on 9 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Phibro Animal Health?

Assembly Biosciences (NASDAQ:ASMB) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

Assembly Biosciences has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Phibro Animal Health has a net margin of 6.66% compared to Assembly Biosciences' net margin of -16.57%. Phibro Animal Health's return on equity of 35.88% beat Assembly Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Assembly Biosciences-16.57% -4.40% -3.86%
Phibro Animal Health 6.66%35.88%9.16%

Assembly Biosciences currently has a consensus target price of $46.50, indicating a potential upside of 120.17%. Phibro Animal Health has a consensus target price of $46.50, indicating a potential upside of 29.27%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than Phibro Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Assembly Biosciences
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Phibro Animal Health
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Phibro Animal Health has higher revenue and earnings than Assembly Biosciences. Phibro Animal Health is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Assembly Biosciences$72.30M5.95-$6.12M$1.0220.71
Phibro Animal Health$1.52B0.96$99.72M$2.5114.33

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 3.5% of Assembly Biosciences shares are owned by company insiders. Comparatively, 48.5% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Assembly Biosciences had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 7 mentions for Assembly Biosciences and 6 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.23 beat Assembly Biosciences' score of -0.68 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Assembly Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Negative
Phibro Animal Health
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Phibro Animal Health beats Assembly Biosciences on 9 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Assembly Biosciences has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$51.95M26.30-$265.94M-$1.46N/A
Assembly Biosciences$72.30M5.95-$6.12M$1.0220.71

Ocular Therapeutix has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by insiders. Comparatively, 3.5% of Assembly Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Ocular Therapeutix had 28 more articles in the media than Assembly Biosciences. MarketBeat recorded 35 mentions for Ocular Therapeutix and 7 mentions for Assembly Biosciences. Ocular Therapeutix's average media sentiment score of -0.06 beat Assembly Biosciences' score of -0.68 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ocular Therapeutix
6 Very Positive mention(s)
3 Positive mention(s)
12 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
Assembly Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Negative

Ocular Therapeutix currently has a consensus price target of $23.83, indicating a potential upside of 283.79%. Assembly Biosciences has a consensus price target of $46.50, indicating a potential upside of 120.17%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Assembly Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocular Therapeutix
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Assembly Biosciences
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Assembly Biosciences has a net margin of -16.57% compared to Ocular Therapeutix's net margin of -648.64%. Assembly Biosciences' return on equity of -4.40% beat Ocular Therapeutix's return on equity.

Company Net Margins Return on Equity Return on Assets
Ocular Therapeutix-648.64% -59.95% -46.75%
Assembly Biosciences -16.57%-4.40%-3.86%

Summary

Assembly Biosciences beats Ocular Therapeutix on 9 of the 17 factors compared between the two stocks.

How does Assembly Biosciences compare to Innoviva?

Assembly Biosciences (NASDAQ:ASMB) and Innoviva (NASDAQ:INVA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

Assembly Biosciences has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Assembly Biosciences currently has a consensus target price of $46.50, indicating a potential upside of 120.17%. Innoviva has a consensus target price of $39.00, indicating a potential upside of 104.94%. Given Assembly Biosciences' higher possible upside, research analysts clearly believe Assembly Biosciences is more favorable than Innoviva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Assembly Biosciences
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Innoviva
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

Innoviva has a net margin of 44.13% compared to Assembly Biosciences' net margin of -16.57%. Innoviva's return on equity of 22.91% beat Assembly Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Assembly Biosciences-16.57% -4.40% -3.86%
Innoviva 44.13%22.91%16.67%

Innoviva has higher revenue and earnings than Assembly Biosciences. Innoviva is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Assembly Biosciences$72.30M5.95-$6.12M$1.0220.71
Innoviva$438.32M3.09$271.17M$1.999.56

In the previous week, Assembly Biosciences had 1 more articles in the media than Innoviva. MarketBeat recorded 7 mentions for Assembly Biosciences and 6 mentions for Innoviva. Innoviva's average media sentiment score of 0.64 beat Assembly Biosciences' score of -0.68 indicating that Innoviva is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Assembly Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Negative
Innoviva
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 3.5% of Assembly Biosciences shares are owned by company insiders. Comparatively, 2.0% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Innoviva beats Assembly Biosciences on 10 of the 16 factors compared between the two stocks.

Get Assembly Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ASMB vs. The Competition

MetricAssembly BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$410.88M$13.76B$7.83B$11.75B
Dividend YieldN/A2.58%2.47%4.41%
P/E Ratio24.9129.0734.3430.11
Price / Sales6.007.748.005.34
Price / CashN/A15.7421.0222.34
Price / Book1.635.194.763.85
Net Income-$6.12M$2.88B$3.52B$393.14M
7 Day Performance-2.29%-3.87%-5.34%-4.53%
1 Month Performance5.97%-3.96%-3.61%-5.86%
1 Year Performance-42.00%-7.13%0.01%-7.78%

Assembly Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ASMB
Assembly Biosciences
2.1051 of 5 stars
$21.29
+0.8%
$46.50
+118.4%
-42.5%$410.88M$72.30M24.9173
ANIP
ANI Pharmaceuticals
3.6278 of 5 stars
$69.62
-2.8%
$99.60
+43.1%
-15.0%$1.60B$883.37M15.00970
PCRX
Pacira BioSciences
2.7058 of 5 stars
$36.42
+0.1%
$33.33
-8.5%
+53.3%$1.45B$746.16M104.06829
PAHC
Phibro Animal Health
4.1904 of 5 stars
$35.40
-10.2%
$47.67
+34.7%
-20.2%$1.44B$1.52B14.512,605
OCUL
Ocular Therapeutix
2.2999 of 5 stars
$6.43
-9.9%
$23.33
+262.9%
-45.0%$1.41B$52.06MN/A325

Related Companies and Tools


This page (NASDAQ:ASMB) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners